Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Problems with China Trial Data of BMS/Pfizer Blood Thinner Caused Delay in Approval

publication date: Jul 9, 2013
China promotes itself as a great place to conduct global clinical trials. It features low costs and the world’s largest population, most of whom are treatment naïve. But according to documents recently released by the US FDA, the China arm of a global trial caused a nine-month delay in the approval process of Eliquis, a major new product. The reason? There were errors in the data, the wrong drugs may have been administered and adverse events were covered up. More details....

Stock Symbols: (NYSE: BMY) (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China